<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - SOFOSBUVIR</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>SOFOSBUVIR</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#renalImpairment" data-toggle="tab">Renal impairment</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#patientAndCarerAdvice" data-toggle="tab">Patient and carer advice</a></li>
          <li><a href="#nationalFunding" data-toggle="tab">National funding/access decisions</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#prescribingAndDispensingInformation" data-toggle="tab">Prescribing and dispensing</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">In combination with ribavirin (Copegus<tm tmtype="reg"/>), with or without peginterferon alfa, for chronic hepatitis C infection of genotypes 1, 3, 4, 5, or 6 in patients with compensated liver disease</span>,
                <span class="indication">In combination with ribavirin (Copegus<tm tmtype="reg"/>) for chronic hepatitis C infection of genotype 2 in patients with compensated liver disease</span>,
                <span class="indication">In combination with daclatasvir for chronic hepatitis C infection of genotype 1, 3, or 4</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                400 mg once daily, for duration of treatment consult product literature.</li>
            </ul>
          </section>
        </section>
        
        
        
        
        
      </section>



      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <p>Manufacturer advises avoid.</p>
            </section>
      </section>


      <section class="tab-pane" id="renalImpairment">
        <h2>Advice regarding renal impairment</h2>

        
            <section class="generalInformation">
              <p>Safety and efficacy not established if eGFR less than 30&#8239;mL/minute/1.73&#8239;m<sup>2</sup>&#8212;accumulation may occur.</p>
            </section>
      </section>


      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>notKnown:</strong> Abdominal discomfort (in combination with ribavirin), agitation (in combination with ribavirin and peginterferon alfa), alopecia (in combination with ribavirin), anaemia (in combination with ribavirin), anxiety (in combination with ribavirin and peginterferon alfa), arthralgia (in combination with ribavirin), asthenia (in combination with ribavirin), blurred vision (in combination with ribavirin and peginterferon alfa), chest pain (in combination with ribavirin and peginterferon alfa), constipation (in combination with ribavirin), cough (in combination with ribavirin), decreased appetite (in combination with ribavirin and peginterferon alfa), depression (in combination with ribavirin), diarrhoea (in combination with ribavirin and peginterferon alfa), disturbance in attention (in combination with ribavirin), dizziness (in combination with ribavirin and peginterferon alfa), dry mouth (in combination with ribavirin and peginterferon alfa), dyspnoea (in combination with ribavirin), gastro-oesophageal reflux (in combination with ribavirin), headache (in combination with ribavirin), influenza-like symptoms (in combination with ribavirin), insomnia (in combination with ribavirin), irritability (in combination with ribavirin), memory impairment (in combination with ribavirin and peginterferon alfa), migraine (in combination with ribavirin and peginterferon alfa), myalgia (in combination with ribavirin), nausea (in combination with ribavirin), neutropenia (in combination with ribavirin and peginterferon alfa), rash (in combination with ribavirin), vomiting (in combination with ribavirin and peginterferon alfa), weight loss (in combination with ribavirin and peginterferon alfa),
              </p>
        
        
        
      </section>


      <section class="tab-pane" id="patientAndCarerAdvice">
        <h2>Advice for patients and carers</h2>

            <section class="adviceAroundMissedDoses">
              <p>If a dose is more than 18 hours late, the missed dose should not be taken and the next dose should be taken at the normal time.</p>
            </section>
      </section>

      <section class="tab-pane" id="nationalFunding">
        <h2>National funding/access decisions</h2>

            <section class="niceTechnologyAppraisals">
              <h3 class="fundingIdentifier">NICE TA330</h3>
              <p outputclass="title">Sofosbuvir for treating chronic hepatitis C (February 2015)</p> <p>Sofosbuvir in combination with peginterferon alfa and ribavirin is an option for treating adults with chronic hepatitis C infection:</p> <ul> <li>of genotype 1</li> <li>of genotype 3 with cirrhosis (treatment naive patients)</li> <li>of genotype 3 that has not adequately responded to interferon-based treatment</li> <li>of genotype 4, 5, or 6 with cirrhosis</li> </ul> <p>Sofosbuvir in combination with ribavirin is an option for treating adults with chronic hepatitis C infection:</p> <ul> <li>of genotype 2 who are intolerant to <i>or</i> ineligible for interferon (treatment naive patients)</li> <li>of genotype 2 that has not adequately responded to interferon-based treatment</li> <li>of genotype 3 with cirrhosis who are intolerant to <i>or</i> ineligible for interferon (treatment naive patients)</li> <li>of genotype 3 with cirrhosis that has not adequately responded to interferon-based treatment</li> </ul><xref format="html" href="http://www.nice.org.uk/TA330">www.nice.org.uk/TA330</xref>
                <a href="http://www.nice.org.uk/TA330" target="_blank">www.nice.org.uk/TA330</a>
            </section>
            <section class="niceTechnologyAppraisals">
              <h3 class="fundingIdentifier">NICE TA330</h3>
              <p outputclass="title">Sofosbuvir for treating chronic hepatitis C (February 2015)</p> <p>Sofosbuvir in combination with ribavirin is not recommended for the treatment of adults with chronic hepatitis C infection of genotypes 1, 4, 5, or 6.</p><xref format="html" href="http://www.nice.org.uk/TA330">www.nice.org.uk/TA330</xref>
                <a href="http://www.nice.org.uk/TA330" target="_blank">www.nice.org.uk/TA330</a>
            </section>
      </section>


      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            <p>In chronic hepatitis C of genotype 1, 4, 5, or 6, only use sofosbuvir with ribavirin in those with intolerance or contra-indications to peginterferon alfa who require urgent treatment.</p>
          </li>
        </ul>
      </section>




      <section class="tab-pane" id="prescribingAndDispensingInformation">
        <h2>Information regarding prescribing and dispensing</h2>

            <section class="prescribingAndDispensingInformation">
              <p>Dispense in original container (contains desiccant).</p>
            </section>
      </section>









      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of SOFOSBUVIR</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        

            <div id="PHP101313"><a href="../medicinalForm/PHP101313.html" data-target="#PHP101313" data-action="load">Tablet</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
